Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features by Raquel Celis et al.
RESEARCH ARTICLE Open Access
Synovial cytokine expression in psoriatic arthritis
and associations with lymphoid neogenesis and
clinical features
Raquel Celis1, Núria Planell2, José L Fernández-Sueiro3, Raimon Sanmartí1, Julio Ramírez1, Isidoro González-Álvaro4,
José L Pablos5 and Juan D Cañete1*
Abstract
Introduction: Psoriatic arthritis (PsA) is an autoantibody-negative immune-mediated disease in which synovial
lymphoid neogenesis (LN) occurs. We determined whether LN is associated with specific patterns of inflammatory
cytokine expression in paired synovial tissue (ST) and fluid (SF) samples and their potential correlation with the clinical
characteristics of PsA.
Methods: ST and paired SF samples were obtained from the inflamed knee of PsA patients. ST samples were
immunostained with CD3 (T cell), CD20 (B cell), and MECA-79 (high endothelial vessels). Total ST mRNA was extracted,
and the gene expression of 21 T-cell-derived and proinflammatory cytokines were measured with quantitative real-time
PCR. SF concentrations of Th1, Th2, Th17, and proinflammatory cytokines were determined with the Quantibody
Human Th17 Array. Clinical and biologic data were collected at inclusion and after a median of 27 months of follow-up.
Results: Twenty (43.5%) of 46 patients had LN. Only two genes showed differences (Wilcoxon test, P < 0.06) in ST
between LN-positive and LN-negative patients: interleukin-23A (IL-23A) (P = 0.058) and transforming growth factor-
beta (TGF-b1) (P = 0.050). IL-23A expression was higher, and TGF-b1 expression was lower in LN-positive patients.
ST IL-15 mRNA showed a nonsignificant trend toward higher expression in LN-positive patients, and SF IL-15
protein levels were significantly higher in LN-positive patients (P = 0.002). In all PsA patients, IL-23A mRNA
expression correlated with C-reactive protein (CRP) (r = 0.471; P = 0.001) and swollen-joint count (SJC) (r = 0.350; P
= 0.018), whereas SF levels of IL-6 and CC chemokine-ligand 20 (CCL-20) correlated with CRP levels (r = 0.377; P =
0.014 and r = 0.501; P < 0.0001, respectively).
Conclusions: These findings suggest differences in the cytokine profile of PsA patients with LN, with a higher
expression of IL-23A and IL-15 and a lower expression of TGF-b1. In the entire group of patients, IL-23 ST
expression and CCL20 SF levels strongly correlated with markers of disease activity. This cytokine pattern was not
accompanied by gross clinical or biologic differences between LN-positive and -negative patients. Taken together,
these results suggest a role of the IL-17/IL-23 cytokine axis in synovial LN in PsA.
Introduction
Psoriatic arthritis (PsA) is a chronic, inflammatory, mus-
culoskeletal disease associated with skin psoriasis that is
mediated by the immune system and can lead to signifi-
cant bone and cartilage destruction, functional impair-
ment, and reduced quality of life [1].
Histopathologic analyses of PsA versus rheumatoid
arthritis (RA) synovial tissues have revealed differential
characteristics that may be of potential value in the diag-
nostic classification of patients with undifferentiated
arthritis, although they share basic features [2]. Of these,
ectopic lymphoid neogenesis (LN) has been observed in
similar proportions in patients with RA and PsA [3-5].
LN results from the organized aggregation of T and B
cells around specialized vessels known as high endothe-
lial venules (HEVs), and correlates with the ectopic
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expression of a restricted set of homing chemokines,
which are physiologically involved in the traffic and tissue
compartmentalization of T and B cells in secondary
lymphoid organs [6].
A previous study of patients with PsA and LN by our
group suggested that LN is a stable feature in these
patients that is reversed only after therapeutic remission
[3]. However, its pathogenetic and clinical significance in
RA and PsA patients remains unclear.
LN in PsA patients remains intriguing because no speci-
fic autoantibodies have been described, and because rheu-
matoid factor (RF) and anti-citrullinated protein/peptide
antibodies (ACPAs) are detected in low titers in only a
small proportion of PsA patients [7]. However, B cells and
LN structures could drive antibody-independent synovial
inflammation through the development of specific T-cell
responses or by enhancing cytokine production [8]. This
might result in differences in the disease phenotype
between patients with and without synovial LN, which
might have prognostic interest.
To determine whether synovial LN is associated with
differential patterns of cytokine expression, we quantified
T-cell polarization (Th1/Th2; Th17/IL-23) and proin-
flammatory cytokines in paired synovial tissue (ST) and
fluid (SF) samples of patients with PsA with and without
synovial LN. We also analyzed the potential association
between these mediators and markers of disease activity.
Methods
Patients and synovial tissues
Synovial biopsy specimens were obtained with needle
arthroscopy from patients of Hospital Clinic (Barcelona,
Spain) and Complejo Hospitalario Universitario, (La Cor-
uña, Spain) meeting the CASPAR criteria for PsA [9],
selected according to the presence of active knee synovitis
(pain and inflammatory synovial fluid). Paired synovial
fluid samples were also obtained at the same time from 42
of these patients. All patients gave informed consent, and
the study was approved by the Ethics Committee of the
Hospital Clinic of Barcelona, Barcelona, Spain.
Arthroscopy was performed under diagnostic and/or
therapeutic (lavage) conditions with a 2.7-mm arthro-
scope (Storz, Tullingen, Germany). Eight synovial tissue
samples were obtained from the suprapatellar pouch and
the medial and lateral gutter in each patient [3]. Four
samples were fixed in 4% formaldehyde and embedded in
paraffin wax for immunohistochemistry, and the remain-
ing four, collected on RLT lysis buffer (Qiagen, Crawley,
West Sussex, UK for RNA extraction.
Patients were evaluated every 3 to 4 months, and the
treatment was changed if the disease remained active (that
is, DAS28 > 3.2 or ≥ 2 swollen and tender joints). Therapy
with methotrexate was initiated (up to 20 mg/week if tol-
erated), and if no response occurred or adverse events
were noted, patients were switched to anti-TNF-a or to
combined therapy, according to their rheumatologist’s
judgment. Clinical and biologic data (joint pattern,
DAS28, C-reactive protein (CRP) and erythrocyte sedi-
mentation rate (ESR), disease-modifying antirheumatic
drugs (DMARDs), and biologic therapy administered)
were collected at study inclusion and the last clinical
control. Psoriasis severity at inclusion was evaluated by
Physician Global Assessment [10].
Immunohistochemistry
Sequential sections of PsA synovial tissues were analyzed
for the presence of lymphoid aggregates and the expres-
sion of the following markers by peroxidase immunohisto-
chemical analysis. T cells were labeled with polyclonal
rabbit anti-human CD3 (A0452; DAKO, Cambridge, UK);
B cells, with mouse anti-human CD20 (clone L26,
DAKO); and HEV, with rat anti-human PNAd (clone
MECA-79; PharMingen, Oxford, UK). Antigen retrieval,
which was required for most antibodies, was performed
with microwave heating in 1 mM EDTA for 15 minutes.
Primary antibodies were developed with appropriate
secondary biotinylated antibodies according to a biotin
peroxidase-based method (ABC; Vector Laboratories,
Burlingame, CA, USA), by using diaminobenzidine as
chromogen. Sections were counterstained in Gill
hematoxylin.
Analysis of lymphoid aggregates
The highest grade of lymphoid aggregation within each
synovial tissue sample was determined according to a pre-
viously described scoring method [11] based on the num-
ber of radial cell counts: grade 1, two to five radial cell
counts; grade 2, six to 10 radial cell counts; and grade 3,
more than 10 radial cell counts. The presence of T/B cell
segregation and PNAd+ HEV within lymphoid aggregates
was analyzed.
Real-time quantitative PCR
Total RNA was extracted from ST samples of 46 PsA
patients by using the RNeasy FFPE Kit (Qiagen) according
to the manufacturer’s recommendations. cDNA was
synthesized by using a high-capacity cDNA archive kit
(Applied Biosystems, Warrington, UK). The primers for
CCR7, IFN-g, IL-1b, IL-2, IL-6, IL-7, IL-8, IL-10, IL-12A,
IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL-23A, IL-28, IL-
33, TGF-b1, TNF- a, and lymphotoxin (LTb), were pur-
chased from Applied Biosystems, and gene expression was
measured with duplicate quantitative real-time PCR by
using the TaqMan Gene Expression Assay (Applied
Biosystems).
The expression of 23 target genes and one housekeeping
gene (GAPDH) was measured with qPCR. To quantify
transcript levels, target-gene Ct values were normalized by
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using the DeltaCt method (ΔCt = Ct reference gene - Ct
target gene). Fold changes were calculated by using the
differences of medians of the two groups, and a nonpara-
metric Mann-Whitney-Wilcoxon test was used to examine
statistically different expression patterns between groups.
A P value of ≤ 0.05 was considered statistically significant.
Ct values were calculated by using the SDS 2.4 and RQ
Manager software (Applied Biosystems).
Quantification of cytokines in synovial fluid
SF cytokines were analyzed by using Quantibody Human
TH17 Array 1 (GM-CSF, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12p70, IL-13, IL-17A, IL-17F, IL-21, IL-22, IL-23,
IFN-g, CCL20, TGF-b1, TNF-a, and TNF-b) (RayBiotech,
Norcross, GA, USA), according to the manufacturer’s spe-
cifications. Each sample was prepared in quadruplicate.
An Axon scanner 4000B with GenePix software was used
to collect fluorescence intensities. Detection limits for
cytokines are displayed on the manufacture’s website [12].
IL-15 levels in synovial fluid supernatants were mea-
sured with enzyme-linked immunoassay (ELISA), as pre-
viously described [13].
Statistical analysis
Numeric variables were described as median and inter-
quartile range (IQR), and categoric variables, as frequen-
cies and percentages. The Wilcoxon Rank Sum test or
Kruskal-Wallis test was used to compare the distribution
of numeric variables between groups.
The Fisher Exact test was used to compare categoric
variables. Correlation between numeric variables was
expressed by Spearman correlation coefficient, and the
null hypothesis was tested (coefficient = zero).
Correlation between two categoric variables or between
one numeric and one categoric variable was assessed by
using the Fisher Exact test and the Wilcoxon Rank Sum
test or Kruskal-Wallis test. Univariate and multivariate
logistic regression models were performed to evaluate
association with LN, and the area under the curve (AUC)
of the receiver operating characteristic (ROC) curve was
used to assess the performance of prediction models. Clas-
sifiers with an AUC > 0.5 have at least some ability to dis-
criminate between groups. All analyses were performed by
using R statistical environment, version 2.12.1 [14].
Results
Clinical and demographic data
Forty-six PsA patients (57% male), aged (median; IQR) 50
(37; 61) years were included; disease duration at inclusion
was 7.5 years (3.7; 13), and follow-up time after inclusion
was 27 months (9; 52). Twenty-three (50%) patients had
oligoarthritis, 18 (39%), polyarthritis, and five (11%),
mixed-pattern (peripheral arthritis with axial involvement.
PGA was 21 (46%) clear, 22 (48%) mild, and three (6%)
moderate.
C-reactive protein (CRP) was 0.7 (0.3; 2) mg/dl; TJC, 1
(1; 2); SJC, 1 (1; 2); and DAS28, 3.3 (3; 4.2). Three
patients were RF positive at low titers (< 80 U/mL), and
no patient was ACPA positive (> 25 U/mL) (Table 1).
Twenty-eight (60.3%) patients were treated during the
follow-up: 23 with methotrexate, three of them combined
with TNF-blockers, and five with TNF-blockers in mono-
therapy. In this cohort, the main target of treatment was
arthritis. LN-negative patients were treated with signifi-
cantly more TNF-blockers than were LN-positive patients,
but this finding could reflect differences in the rheumatol-
ogist criteria (Table 1).
Twelve (26%) patients had erosive disease at the end
of follow-up, without differences between LN-positive
and -negative patients.
Of the 28 patients treated during follow-up, 71%
achieved a EULAR response (46% good and 25% moder-
ate), without differences between LN-positive and -nega-
tive patients (Table 1).
Synovial cytokine expression in the entire group of PsA
patients
All 21 cytokine genes studied were expressed in ST in
most patients, although some were expressed in fewer
than 50% of patients (IL-13, IL-17A, IL-21, IL-22, and IL-
28A). In SF, IL-12 and IL-28A were not detected at all,
and some cytokines were detected in only a small percen-
tage of patients in comparison with mRNA expression.
The exceptions were SF IL-6, IL-15, and CCL20, which
were detected in either ST or SF in > 80% of patients
(Tables 2 and 3). No correlation was found between the
two compartments for any cytokine, probably because of
the dissociation of cytokine expression between ST and
SF.
Correlation of cytokines with markers of disease activity
IL-23 A mRNA expression was correlated with CRP (r =
0.471; P = 0.001) and SJC (r = 0.350; P = 0.018),
whereas SF levels of IL-6 and CCL-20 correlated with
CRP levels (r = 0.377; P = 0.014; and r = 0.501; P <
0.0001, respectively).
Synovial cytokines and lymphoid neogenesis
Twenty (43.5%) patients had synovial LN (follicular aggre-
gates grade ≥ 2 with T/B cell segregation and HEV). Pre-
vious studies in RA showed a good correlation between
LN and the expression of cytokines IL-7 and LTb and sev-
eral homing chemokines and their receptors [15]. In our
PsA cohort, a modest, nonsignificant increase in CCR7,
IL-7, and LTb mRNA expression was detected in LN-posi-
tive patients (Table 2 and Figure 1). Differences between
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Table 1 Clinical and biologic characteristics of patients stratified by lymphoid neogenesis
Demographic All (n = 46) LN+ (n = 20) LN- (n = 26) P
Age (years) 50 (37; 61) 48 (36; 59) 54 (38.5; 63) NS
Male (%) 26 (57) 13 (65) 13 (50) NS
Disease duration (years) 7.5 (3.75; 13) 6 (2; 14) 8 (4.5; 12.5) NS
Follow-up (months) 27 (9; 52) 21 (8; 50) 27 (12; 55) NS
Clinical status
TJC 1 (1; 2) 1 (1; 2) 1 (1; 2) NS
SJC 1 (1; 2) 1 (1; 2) 1 (1; 2) NS
Articular pattern, n (%)
Oligoarthritis 23 (50) 13 (57) 10 (43) NS
Poliarthritis 18 (39) 7 (39) 11 (61)
Mixed (peripheral plus axial) 5 (11) 2 (40) 3 (60)
ESR (mm/h) 19 (10; 30) 20 (9; 31) 18 (12; 25) NS
CRP (mg/dl) 0.72 (0.32; 2.01) 1.00 (0.51; 1.83) 0.44 (0.29; 2.32) NS
DAS28 3.31 (3.01; 4.2) 3.31 (2.94; 4.14) 3.34 (3.01; 4.28) NS
Erosive disease, n (%) 12 (26) 7 (35) 5 (19) NS
Treatment
DMARDs taken, n (%) 23 (50) 12 (60) 11 (42) NS
TNF-blockers, n (%) 8 (17) 1 (5) 7 (27) 0.041
EULAR response Treated (n = 28) LN+ (n = 11) LN- (n = 17) P
No response, n (%) 8 (29) 3 (27) 5 (29) 0.541
Moderate, n (%) 7 (25) 4 (36) 3 (18)
Good, n (%) 13 (46) 4 (36) 9 (53)
Data are expressed as median (IQR) or as percentage.
Table 2 RT-PCR of 21 cytokine genes expressed as Delta Ct value and stratified by LN
n (%) of positive patients All n = 46 LN+ n = 20 (43.5%) LN- n = 26 (52.4%) Wilcoxon P value
CCR7 45 (98%) 8 (-10; -7) -8 (-9; -7) -8 (-10; -7) 0.465
IFN-g 35 (76%) -10 (-12; -9) -10 (-11; -9) -11 (-12; -8) 0.656
IL-10 45 (98%) -7 (-8; -6) -7 (-8; -7) -7 (-8; -6) 0.312
IL-12A 41 (89%) -9 (-10; -8) -9 (-10; -8) -10 (-11; -8) 0.188
IL-13 11 (24%) -14 (-15; -13) -15 (-16; -15) -13 (-14; -11) 0.109
IL-15 42 (91%) -9 (-9; -8) -8 (-9; -8) -9 (-10; -8) 0.104
IL-17A 15 (33%) -11 (-13; -9) -13 (-14; -11) -11 (-11; -9) 0.121
IL-18 46 (100%) -6 (-7; -6) -7 (-7; -6) -6 (-7; -5) 0.418
IL-1b 43 (94%) -8 (-9; -7) -9 (-9; -8) -8 (-9; -7) 0.517
IL-2 29 (59%) -12 (-14; -11) -13 (-14; -11) -12 (-14; -12) 0.846
IL-21 20 (43%) -13 (-14; -12) -13 (-14; -12) -13 (-14; -12) 0.909
IL-22 7 (15%) -12 (-14; -11) -13 (-15; -12) -11 (-13; -11) 0.629
IL-23A 45 (98%) -5 (-6; -5) -5 (-6; -4) -6 (-8; -5) 0.058
IL-28A 21 (46%) -10 (-12; -9) -10 (-12; -8) -11 (-11; -10) 0.622
IL-33 41 (89%) -11 (-12; -9) -11 (-12; -9) -11 (-12; -9) 0.646
IL-6 44 (96%) -8 (-10; -6) -8 (-9; -7) -8 (-10; -5) 0.706
IL-7 44 (96%) -6 (-7; -6) -6 (-7; -5) -7 (-7; -6) 0.608
IL-8 46 (100%) -4 (-6; -2) -4 (-5; -3) -3 (-6; -2) 0.877
LTb 44 (96%) -6 (-8; -5) -6 (-7; -5) -6 (-8; -6) 0.443
TGF-b1 46 (100%) -3 (-4; -2) -3 (-4; -3) -3 (-3; -2) 0.050
TNF-a 46 (100%) -7 (-8; -6) -7 (-8; -6) -7 (-8; -6) 0.816
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LN-positive and -negative patients (Wilcoxon P < 0.06)
were found in ST in only two genes: IL-23A (P = 0.058)
and TGF-b1 (P = 0.05). The expression of IL-23A was
higher in LN-positive patients, and that of TGF-b1 was
higher in LN-negative patients (Table 2 and Figure 2). The
combination of IL-23A and TGF-b1 in a multivariate logis-
tic regression model of factors influencing LN confirmed
these genes as predictors of LN [AUC, 0.736; 95% CI,
0.5897 to 0.8823; IL-23 A, OR, 1.62 (1.06 to 2.48); P =
0.027; TGF-b1, OR, 0.72 (0.05 to 1.03), P = 0.075)].
However, TGF-b1 mRNA expression correlated with
the number of B-cell grade 3 aggregates (r = 0.363; P =
0.046) and with the percentage of B cells in synovial sam-
ples (r = 0.508; P = 0.005). Although not significantly
higher in LN-positive patients, IL-21 mRNA expression
strongly correlated with the number of B-cell grade 3
aggregates (r = 0.686; P = 0.0048).
ST IL-15 mRNA was higher in LN-positive patients,
with only a trend to significance (Wilcoxon P = 0.104)
(Table 2). In SF, only IL-15 levels were significantly higher
in LN-positive patients (Wilcoxon P = 0.0023; Table 2).
Accordingly, SF IL-15 levels correctly classified patients as
LN positive or negative (AUC, 0.791; 95% CI, 0.64 to
0.941; Table 3).
Discussion
It has been suggested that ectopic LN might play a role
in the pathogenesis of chronic inflammatory conditions
by driving T-cell responses and producing proinflamma-
tory cytokines [16]. The proportion of our PsA patients
showing LN features is similar to that described pre-
viously and also to that of studies in RA [3,4]. The clini-
cal significance of ectopic LN has recently been
analyzed in RA, in which several studies point to more-
refractory disease [4], greater inflammation [17], and
more-erosive disease in this subset of patients [18].
Our study provides the first approach to this issue in
PsA. Because PsA is not associated with B-cell responses,
it represents a good model to explore whether T-cell
polarization can be modified by LN, independent of B-cell
responses. Our results show that PsA patients with syno-
vial LN have a higher expression of IL-23A and a lower
expression of TGF-b1 in synovial tissue compared with
LN-negative patients. The combination of these two genes
in a multivariable logistic regression model confirmed that
they were associated with LN. Additional differences of
lower magnitude in IL-15 and IL-21 mRNA expression
also pointed to subtle differences in the cytokine profile of
this PsA subset.
An unexpected finding of our study is the weaker cor-
relation between molecular markers of LN, such as
CCR7, IL-7, and LTb, and LN, as defined by T-/B-cell
aggregates, T/B compartmentalization, and MECA-79
epitope expression. The expression of these factors has
been associated with synovial LN in RA patients and
experimental animal models [6,19-21]. It is possible that
Table 3 Cytokine levels (pg/mL) in patients with PsA stratified by LN
n (%) of positive patients All n = 42 LN+ n = 20 (47.6%) LN- n = 22 (52.4%) Wilcoxon P value
GM.CSF 4 (10%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.051
IFN-g 6 (14%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.444
IL-1b 7 (7%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.632
IL-2 21 (50%) 42 (0; 133) 0 (0; 151) 83 (0; 119) 0.851
IL-4 2 (2%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.365
IL-5 19 (19%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.440
IL-6 41 (98%) 1241 (503; 1,544) 1324 (764; 1,496) 1093 (258; 1,720) 0.462
IL-10 22 (52%) 4 (0; 13) 4.4 (0; 12) 0 (0; 14) 0.926
IL-12p70 0 0 (0; 0) 0 (0; 0) 0 (0; 0) NA
IL-13 4 (10%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.348
IL-15 38 (91%) 114 (47; 197) 180 (109; 261) 62 (23; 115) 0.002
IL-17 11 26%) 0 (0; 20) 0 (0; 7) 0 (0; 26) 0.757
IL-17F 12 (29%) 0 (0; 12) 0 (0; 6) 0 (0; 12) 0.728
IL-21 19 (45%) 0 (0; 817) 0 (0; 773) 0 (0; 958) 0.591
IL-22 1 (2%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.317
IL-23 15 (36%) 0 (0; 212) 0 (0; 190) 0 (0; 262) 0.758
IL-28A 0 0 (0; 0) 0 (0; 0) 0 (0; 0) NA
CCL20 34 (81%) 37 (6; 497) 23 (7; 284) 40 (1; 624) 0.752
TGF-b1 8 (19%) 0 (0; 0) 0 (0; 0) 0 (0; 446) 0.157
TNF-a 4 (10%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.323
TNF-b 7 (17%) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0.684
Data are expressed as median (IQR). NA, not applicable.
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the wide variation in the extension of lymphoid aggre-
gates in different tissues, and the different histologic cri-
teria used to identify LN may explain the variable
associations of LN with molecular markers and disease
severity found in different studies analyzing lymphocyte
aggregation and organization [22]. This could lead to
contradictory findings, as is the case with ST TGF-b1
mRNA expression, which was higher in LN-negative
patients, but paradoxically, it correlated with B-cell
aggregates grade 3 and strongly with the percentage of
B cells in ST. Supporting this hypothesis, we specifically
find a strong correlation between mature B-cell aggre-
gates and IL-21 mRNA expression, but no significant
differences according to LN classification.
We found an association between higher IL-23A mRNA
expression and LN. Furthermore, IL-23A mRNA expres-
sion significantly correlated with SJC and CRP, and we
noted a strong trend to correlate with DAS28. This finding
did not correlate with the level of IL-23 in the SF, in which
only a third of these patients had detectable IL-23.
IL-23 is expressed mainly by macrophages and dendri-

































Figure 1 Distribution of mRNA of all cytokines studied according their higher relative expression (fold change) as lymphoid
neogenesis (LN) positive (+) or negative (-).
p = 0.050 p = 0.058 p = 0.002 
Negative Positive Negative Positive Negative Positive 
LN LN LN 
Figure 2 Differential expression of TGF-b1 and IL-23A mRNA in synovial tissue, and IL-15 levels in synovial fluid, according to
lymphoid neogenesis (LN) status.
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survival of Th17 cells and in IL-17 production by non-T
cells [23]. IL-23 acts as an end-stage effector cytokine
through direct action on macrophages [24], the main
producers of proinflammatory cytokines in synovium.
This mechanism of action is in line with our finding of
a positive correlation between IL-23A ST expression
and systemic markers of inflammation. However, a cor-
relation between (serum) IL-23 levels and disease activ-
ity has previously been reported only in patients with
RA [25,26].
The role of IL-23 in the pathogenesis of PsA is less clear.
Genetic studies have confirmed the association of IL-23A
and IL-23R genes with PsA susceptibility, underlining its
potential pathogenetic relevance [27,28]. In addition, uste-
kinumab, an anti-IL-12/IL-23 antibody, has shown efficacy
in PsA patients [29]. In ankylosing spondylitis, a disease
grouped together with PsA in the concept of spondyloar-
thritis, a potential role for IL-23 has also been proposed
[30]. Further research may better define the pathways
through which IL-23 is produced and exerts its actions in
PsA.
In this series, IL-15 mRNA was expressed in grossly
90% of paired ST and SF samples. Previous studies also
detected IL-15 in PsA ST [31,32]. IL-15 stimulates the
production of IL-17 in synovial monocytes and synergizes
with IL-23 to increase IL-17 production. Additional
effects on T- and B-cell survival and monocytes, mast
cells, and neutrophils activation might also contribute to
PsA pathogenesis [33,34]. In RA, IL-15 serum levels cor-
related with disease activity and may predict a severe dis-
ease course [35]. Our data show higher IL-15 expression
in LN-positive patients, supporting its potential pathoge-
netic role. Overall, IL-15 and IL-23 expression would
point to a link between LN and the Th17/IL-23 axis.
However, the expression of Th17-related cytokines was
moderate (IL-17A and IL-21) or very low (IL-22) in ST
and SF, which may be in line with the low abundance of
Th17 cells in PsA or SpA ST, in which the majority of
IL-17-producing cells are non-T cells [36].
Regarding other factors potentially implicated in T-cell
traffic and differentiation, in our study, SF CCL20 levels
correlated with markers of inflammation. Previously a
correlation was reported between SF CCL20 levels and
the number of SF PMNs in PsA, but not with markers of
disease activity [25]. CCL20 is a chemokine that attracts
several types of cells, predominantly Th17 cells expres-
sing the CCR6 receptor. In addition, it has been reported
that IL-17F induces CCL20 production [37]. Upregula-
tion of IL-23 and CCL20 in PsA supports the role of the
IL-17/IL-23 axis disturbance in this disease. As expected,
SF IL-6 levels correlated with CRP levels [38].
TGF-b1 is a multifaceted cytokine participating in
many biologic processes: inflammation, fibrosis, lympho-
cyte recruitment, and lymphocyte-effector differentiation
(Treg and Th17) [39]. Given that no previous reports
exist of TGF-b1 in PsA, it is difficult to ascertain the
clinical significance of the lower expression of these
cytokines in LN in this disease.
Although these data suggest that synovial LN might be
associated with a distinctive cytokine profile with a
more-inflammatory phenotype, we found no clinical dif-
ferences between LN-positive and -negative patients.
Our study has some limitations. First, all samples of
ST and SF are from knee arthritis, which may not be
representative of other inflamed joints in the same
patient. However, previous studies in RA patients sug-
gested that ST from an active joint is a good representa-
tion of other active joints in the same patient [40].
Another limitation is that this is a retrospective study,
with established disease in the majority of patients,
when the ideal scenario for evaluating the clinical signif-
icance of LN might be early untreated PsA patients [22].
Nevertheless, our exploratory study identifies some dif-
ferences in the cytokine profile that support the exis-
tence of pathogenetic differences in the LN-positive PsA
subset.
Conclusion
The results of this study suggest differences in the cyto-
kine profile of PsA patients with LN, with a higher
expression of IL-23A and IL-15 and a lower expression
of TGF-b1. This cytokine pattern was not accompanied
by gross clinical or biologic differences between LN-
positive and -negative patients. In the entire group of
patients, IL-23A ST expression and CCL20 SF levels
strongly correlated with markers of disease activity.
Taken together, these results suggest a role of the IL-
17/IL-23 axis in synovial LN in PsA.
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